These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1060 related articles for article (PubMed ID: 18463509)

  • 1. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
    Smith BT; Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA
    Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
    Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
    Retina; 2006; 26(9):988-93. PubMed ID: 17151484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R; Gabric N
    Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.
    Spaide RF; Sorenson J; Maranan L
    Ophthalmology; 2003 Aug; 110(8):1517-25. PubMed ID: 12917166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis.
    Parodi MB; Iacono P; Kontadakis DS; Zucchiatti I; Cascavilla ML; Bandello F
    Arch Ophthalmol; 2010 Sep; 128(9):1100-3. PubMed ID: 20837791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-vascular endothelial growth factor monotherapy versus combination treatment with photodynamic therapy for subfoveal choroidal neovascularization secondary to causes other than age-related macular degeneration.
    Chen L; Miller JW; Vavvas D; Kim IK
    Retina; 2011 Nov; 31(10):2078-83. PubMed ID: 21691258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study.
    Saviano S; Leon PE; Mangogna A; Tognetto D
    Digit J Ophthalmol; 2016; 22(2):46-53. PubMed ID: 27582675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
    Bakri SJ; Couch SM; McCannel CA; Edwards AO
    Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.
    Bashshur ZF; Schakal A; Hamam RN; El Haibi CP; Jaafar RF; Noureddin BN
    Arch Ophthalmol; 2007 Oct; 125(10):1357-61. PubMed ID: 17923543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.
    Augustin AJ; Schmidt-Erfurth U
    Ophthalmology; 2006 Jan; 113(1):14-22. PubMed ID: 16360209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.
    Ladewig MS; Karl SE; Hamelmann V; Helb HM; Scholl HP; Holz FG; Eter N
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):17-25. PubMed ID: 17701197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia.
    Parodi MB; Iacono P; Papayannis A; Sheth S; Bandello F
    Arch Ophthalmol; 2010 Apr; 128(4):437-42. PubMed ID: 20142520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
    Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
    Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab).
    Ehmann D; García R
    Can J Ophthalmol; 2010 Feb; 45(1):36-40. PubMed ID: 20130708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy in exudative age-related macular degeneration: visual outcomes following combined treatment with photodynamic therapy and intravitreal bevacizumab.
    Wan MJ; Hooper PL; Sheidow TG
    Can J Ophthalmol; 2010 Aug; 45(4):375-80. PubMed ID: 20648087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.